SCHEMBL2969099

SCHEMBL2969099

CCCc1ccc2c(Nc3cc(C)ccc3Sc3cccc(NC(=O)CN)c3)ccnc2n1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 1/20 0.38
RECQL P46063 1/20 0.35
L3MBTL1 Q9Y468 1/20 0.35
SIRT2 Q8IXJ6 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
EGFR P00533 1/20 0.35
PANK1 Q8TE04 2/20 0.35
PANK3 Q9H999 2/20 0.35
PANK2 Q9BZ23 1/20 0.35
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
KDM4E B2RXH2 1/20 0.34
PDE10A Q9Y233 1/20 0.34
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
MET P08581 2/20 0.33
ALK Q9UM73 2/20 0.33
MAPT P10636 1/20 0.33
ITGB3 P05106 1/20 0.33
ITGAV P06756 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2955721 0.93 KDR (0.39) KDRSMN1; SMN2PANK1PANK3PANK2
SCHEMBL2969097 0.91 KDR (0.37) KDRRECQLL3MBTL1SIRT2SMN1; SMN2
SCHEMBL2957726 0.90 KDR (0.38) KDRSIRT2SMN1; SMN2PANK1PANK3
SCHEMBL2967457 0.86 MAPT (0.40) KDRSMN1; SMN2ALDH1A1HPGDKDM4E
SCHEMBL2960103 0.86 KDM4E (0.33) KDM4E
SCHEMBL2968500 0.86 RET (0.39) ALDH1A1MEN1KMT2AMETMAPT
SCHEMBL2969808 0.86 MEN1 (0.37) KDRSMN1; SMN2ALDH1A1KDM4EMEN1
SCHEMBL2957625 0.86 SMN1; SMN2 (0.36) KDRL3MBTL1SMN1; SMN2PANK1PANK3
SCHEMBL2960105 0.85 HTR1A (0.32) L3MBTL1ALDH1A1MAPT
SCHEMBL2965230 0.85 SREBF2 (0.37) L3MBTL1SMN1; SMN2ALDH1A1KDM4EMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8338605-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2012-12-25 US disclosed
US-20100256139-A1 Anti-Viral Compounds ABBOTT LABORATORIES (US) 2010-10-07 US disclosed
EP-1979349-B1 ANTI-VIRAL COMPOUNDS ABBOTT LAB (US) 2010-07-28 EP disclosed
US-7763731-B2 Anti-viral compounds ABBOTT LABORATORIES (US) 2010-07-27 US disclosed
US-20070232645-A1 ANTI-VIRAL COMPOUNDS ABBVIE INC. 2007-10-04 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070232645-A1 ANTI-VIRAL COMPOUNDS HAVCR2, MAVS, EIF2AK2 KDR 3293/4885RECQL 1060/4885L3MBTL1 2884/4885
US-20100256139-A1 Anti-Viral Compounds HAVCR2, MAVS, EIF2AK2 KDR 3293/4885RECQL 1060/4885L3MBTL1 2884/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.